Huddinge 2003-12-05

Nucleoside analogue reverse transcriptase inhibitor 204937 (MIV-210) presented at GlaxoSmithKline R & D day

GlaxoSmithKline (GSK) and Medivir entered a licensing agreement for MIV-210 a nucleoside analogue reverse transcriptase inhibitor (NRTI), in May 2003. GSK is responsible for pharmaceutical development and are having exclusive, worldwide marketing rights, except for the Nordic countries (Denmark, Finland, Iceland, Norway and Sweden), which have been retained by Medivir.

The compound, 204937 (MIV-210) is currently in phase I development for the treatment of HIV. Data regarding this compound was presented during GSK's R & D day on the 3-4th of December 2003.. In vitro data indicate that 204937 is highly effective against a wide range of resistant viruses. More information concerning the project and the recent presentation can be found on www.gsk.com.

About Medivir

Medivir is an innovative, specialist research company that develops pharmaceuticals. The company is located in Huddinge, Sweden and Cambridge, UK. Medivir's research is focused on developing new drug compounds based on proteases and polymerases as target enzymes.

Medivir was floated on the Stockholm Exchange in 1996, and has been quoted on the Attract40 list since 1 July 2003.

Medivir's research portfolio includes projects against HIV, jaundice, shingles, cold sores, osteoporosis, RA (rheumatoid arthritis), asthma and MS (multiple sclerosis). Medivir has five projects in clinical development phases, two of which are about to enter phase III after completing phase II. Two projects are in phase I and one is in phase II. One project—MV026048—is in preclinical development, the stage closest to clinical development. The optimization stage has three projects, the lead identification stage encompasses two projects. Medivir has some ten activities in the first preclinical—explorative—stage.

For information, access our website at www.Medivir.se.

For additional information please contact:
Medivir
Rein Piir, CFO/IR
Phone +46 8 5468 3100 or +46 708 53 72 92